Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years

BACKGROUND: Siponimod significantly reduced the risk of confirmed disability progression (CDP), worsening in cognitive processing speed (CPS), relapses, and magnetic resonance imaging (MRI) measures of brain atrophy and inflammation versus placebo in secondary progressive multiple sclerosis (SPMS) p...

Descripción completa

Detalles Bibliográficos
Autores principales: Cree, Bruce AC, Arnold, Douglas L, Fox, Robert J, Gold, Ralf, Vermersch, Patrick, Benedict, Ralph HB, Bar-Or, Amit, Piani-Meier, Daniela, Rouyrre, Nicolas, Ritter, Shannon, Kilaru, Ajay, Karlsson, Goeril, Giovannoni, Gavin, Kappos, Ludwig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315196/
https://www.ncbi.nlm.nih.gov/pubmed/35380078
http://dx.doi.org/10.1177/13524585221083194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315196/
https://www.ncbi.nlm.nih.gov/pubmed/35380078
http://dx.doi.org/10.1177/13524585221083194

Ejemplares similares